5q- in a case of chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation

Haematologica. 1995 Sep-Oct;80(5):437-9.

Abstract

Clonal chromosome and/or hematological abnormalities typically observed in myelodysplastic syndromes (MDS) have been described with increased frequency after autologous bone marrow transplantation (BMT) for lymphoma. We report the case of a woman with chronic myelogenous leukemia (CML) allografted with her HLA-identical sibling who, 5 years after the transplant and under immunosuppressive treatment for chronic graft host disease (GVHD), suffered a cytogenetic relapse associated with a 5q- deletion in the host metaphases. These findings suggest that myelodysplastic changes, possibly related to the chemo-radiotherapy conditioning regimen, may also present after allogeneic BMT.

MeSH terms

  • Adult
  • Azathioprine / adverse effects*
  • Azathioprine / therapeutic use
  • Bone Marrow Transplantation*
  • Chromosome Deletion*
  • Chromosomes, Human / drug effects
  • Chromosomes, Human / radiation effects
  • Chromosomes, Human, Pair 5 / ultrastructure*
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects*
  • Cyclosporine / therapeutic use
  • Eosinophilia / drug therapy
  • Fasciitis / drug therapy
  • Female
  • Graft vs Host Disease / prevention & control
  • Humans
  • Hydroxyurea / adverse effects*
  • Hydroxyurea / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Methotrexate / therapeutic use
  • Recurrence
  • Whole-Body Irradiation / adverse effects*

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Cyclophosphamide
  • Azathioprine
  • Hydroxyurea
  • Methotrexate